Table 3.
Sensitivity analysis
| Proteins | Follow-Up Duration | |||||
|---|---|---|---|---|---|---|
| 7 Years (n=187 ESKD cases) | 10 Years (n=240 ESKD cases) | 15 Years (n=289 ESKD cases) | ||||
| HR | P | HR | P | HR | P | |
| EFNA4 | 1.95 (1.66 - 2.30) |
7.5 × 10−16 | 1.84 (1.60 - 2.12) |
6.4 × 10−18 | 1.72 (1.52 - 1.94) |
1.6 × 10−17 |
| EFNA5 | 1.55 (1.34 - 1.80) |
7.1 × 10−9 | 1.45 (1.28 - 1.65) |
9.7 × 10−9 | 1.42 (1.27 - 1.60) |
1.4 × 10−9 |
| EPHA2 | 2.15 (1.83 - 2.53) |
3.2 × 10−20 | 1.99 (1.73 - 2.29) |
4.5 × 10−22 | 1.86 (1.65 - 2.11) |
1.1 × 10−22 |
| EPHB2 | 1.55 (1.34 - 1.79) |
3.0 × 10−9 | 1.51 (1.33 - 1.71) |
1.7 × 10−10 | 1.42 (1.26 - 1.59) |
2.6 × 10−9 |
| EPHB6 | 1.83 (1.56 - 2.14) |
9.3 × 10−14 | 1.78 (1.55 - 2.05) |
6.1 × 10−16 | 1.68 (1.48 - 1.90) |
9.0 × 10−16 |
| UNC5C | 1.90 (1.62 - 2.22) |
1.8 × 10−15 | 1.73 (1.51 - 1.98) |
3.4 × 10−15 | 1.70 (1.50 - 1.92) |
2.6 × 10−17 |
Comparison of HRs for time to onset of ESKD during 7, 10, and 15 years of follow-up, according to baseline levels of AGP protein, in the four combined cohorts (n=745). HRs are shown for time to onset of ESKD according to a one-quartile increase (continuous variable) in baseline concentration of the candidate AGP proteins. HR were computed for etiologic models adjusted for sex, duration of diabetes, systolic BP, HbA1c, and eGFR, with variable stratification by study cohort.